Urelumab 

Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL)^[1].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

CD137^[1]

Urelumab (0.3-1 mg/kg, i.p., once every 3 days, 6 times) reduces the tumor volume and tumor weight in humanized 4-1BB mice^[2].
Urelumab (3-30 mg/kg, i.p., once every 3 days, 6 times) exhibits high safety in humanized 4-1BB mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

934823-49-1

Liquid

Colorless to light yellow

[Urelumab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• 
  Immobilized 4-1BB/TNFRSF9 Protein, Human can bind Urelumab. The EC₅₀ for this effect is 12.68 ng/mL.

• [1]. John Timmerman, et al. Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. Am J Hematol. 2020 May;95(5):510-520.  [Content Brief]

  [2]. Cheng LS, et al. A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity. J Transl Med. 2022 Sep 8;20(1):415.  [Content Brief]